BioPharmSignal logoBioPharmSignal

Biotech News

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

Adaptive Biotechnologies (ADPT)Adaptive BiotechnologiesEarnings

SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported

Open original release

Related news

ADPTAdaptive Biotechnologies2026-04-15 20:05 EST

Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

IRIXIRIDEX2026-05-19 20:05 EST

Iridex Reports First Quarter 2026 Financial Results

PAVMPAVmed2026-05-14 12:00 EST

Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results

HYPRHyperfine2026-05-12 20:05 EST

Hyperfine, Inc. Reports First Quarter 2026 Financial Results

ICCMIceCure Medical2026-05-12 12:30 EST

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

CVRXCVRx2026-05-11 20:05 EST

CVRx Reports First Quarter 2026 Financial and Operating Results

TMCITreace Medical Concepts2026-05-08 11:05 EST

Treace Medical Concepts Reports First Quarter 2026 Financial Results

AORTArtivion2026-05-07 20:05 EST

Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan

XTNTXtant Medical2026-05-07 12:00 EST

Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026

SGHTSight Sciences2026-05-06 20:05 EST

Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance

View all latest news

Adaptive Biotechnologies

Adaptive Biotechnologies is a diagnostics and immune-profiling company focused on using immune-sequencing and molecular data to reveal disease signals. Its business is more about immune measurement than classic drug development.

Recent company news

ADPTAdaptive Biotechnologies2026-05-29 11:30 EST

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

ADPTAdaptive Biotechnologies2026-05-05 20:05 EST

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

ADPTAdaptive Biotechnologies2026-04-15 20:05 EST

Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

ADPTAdaptive Biotechnologies2026-02-05 21:05 EST

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

ADPTAdaptive Biotechnologies2026-01-27 21:05 EST

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Stock data

Close
22.54 USD
Market cap
2.42B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States